Insys founder, others lose appeals of opioid convictions
Reuters
Published Aug 25, 2021 06:24PM ET
Updated Aug 25, 2021 07:06PM ET
By Nate Raymond and Jonathan Stempel
BOSTON (Reuters) -A federal appeals court on Wednesday upheld the jury convictions of Insys Therapeutics Inc founder John Kapoor and four other company officials, over their roles in a scheme to bribe doctors to prescribe addictive opioids and defraud insurers into paying for them.
The 1st U.S. Circuit Court of Appeals in Boston ruled 3-0 that "unalloyed greed" drove the defendants to market the fentanyl spray Subsys to "pill mill" doctors, who would then prescribe it to patients with no medical need.
In a 138-page decision, Circuit Judge Bruce Selya wrote that Insys and Kapoor, who had been chief executive, deserved "great credit" for developing Subsys to treat cancer pain, but in the pursuit of profit "turned what should have been a blessing into a curse."
Kapoor, 77, was convicted in 2019 and is serving a 5-1/2-year prison sentence.
He remains the highest-ranking pharmaceutical executive convicted for helping fuel the U.S. opioid epidemic https://www.reuters.com/legal/litigation/us-states-rush-meet-deadline-join-26-billion-opioid-settlement-2021-08-19.
His co-defendants Michael Gurry, Sunrise Lee, Joseph Rowan and Richard Simon were sentenced to terms of one to 2-3/4 years. A lower court judge had set aside some of the jury findings, but the appeals court restored the original verdicts.
"This decision is a decisive win that vindicates the jury's verdict and preserves a just outcome for the defendants and the victims," Acting U.S. Attorney Nathaniel Mendell in Boston said in a statement.
Kapoor's lawyer declined to comment. Lee's lawyer Peter Horstmann said "there are no words to adequately express my displeasure with the court’s opinion." Lawyers for the other defendants did not immediately respond to requests for comment.
Prosecutors said Insys used sham "speaker programs," ostensibly to educate the medical field, as a means to pay bribes and kickbacks to doctors who prescribed Subsys, often to non-cancer patients.
Kapoor also directed efforts to defraud insurers that were reluctant to pay for Subsys, prosecutors said.
Get The News You Want
Fentanyl is up to 100 times stronger than morphine. Insys, based in Chandler, Arizona, filed for bankruptcy in 2019.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.